质谱技术在肿瘤分子诊断中的应用进展
|
摘要
随着医疗技术的迅速发展,肿瘤治疗进入了"精准医学时代"。通过检测相应的标志物,使肿瘤的诊治更具有针对性和特异性,进而显著提高患者的生存。因此,寻找和检测与肿瘤相关的分子标志物至关重要。近年来,质谱技术发展迅速,不仅能定性和定量地分析小分子物质,还能用于检测各种生物分子,如蛋白质、代谢物及核酸等,使得质谱技术迅速成为医药卫生、生物化学、环境监测和石油化工等领域的有力分析工具。因此,本文针对近年来质谱技术在肿瘤分子诊断中的应用进行综述,并对未来的发展趋势进行展望。
With the rapid development of medical technology,we have entered the era of precision medical treatment in cancer.By detecting these biomarkers,the diagnosis and treatment of the tumor are more targeted and specific,which significantly improves the survival of the patients.Therefore,tumor-associated molecular markers are crucial for the new techniques.Recently,mass spectrometry technology has developed rapidly,not only for the qualitative and quantitative analysis of small molecules,but also for the detection of various biomolecules,such as proteins,metabolites and nucleic acids,which has made it an excellent tool in the fields including:medicine and health,biochemistry,environmental monitoring and petrochemical.The article summarizes the application of the technology in molecular diagnosis of tumor and discusses the future development trend.
With the rapid development of medical technology,we have entered the era of precision medical treatment in cancer.By detecting these biomarkers,the diagnosis and treatment of the tumor are more targeted and specific,which significantly improves the survival of the patients.Therefore,tumor-associated molecular markers are crucial for the new techniques.Recently,mass spectrometry technology has developed rapidly,not only for the qualitative and quantitative analysis of small molecules,but also for the detection of various biomolecules,such as proteins,metabolites and nucleic acids,which has made it an excellent tool in the fields including:medicine and health,biochemistry,environmental monitoring and petrochemical.The article summarizes the application of the technology in molecular diagnosis of tumor and discusses the future development trend.
引文
[1]DOMON B,AEBERSOLD R.Mass spectrometry and protein analysis[J].Science,2006,312(5771):212-217.
[2]LENEY A C,HECK A J R.Native mass spectrometry:what is in the name[J]?J Am Soc Mass Spectrom,2017,28(1):5-13.
[3]YANG H,NING L,LIU S.Determination of peptide and protein disulfide linkages by MALDI mass spectrometry[J].Top Curr Chem,2013,331(15):79-116.
[4]LEE M J,KIM H J.Development of an immunoaffinity chromatography and LC-MS/MS method for the determination of 6zearalenones in animal feed[J].PLoS One,2018,13(3):e193584.
[5]CHENG X,LIU K,LIU Y,et al.Development and validation an LCMS/MS method for determination of caspofungin in dried blood spots[J].Rapid Commun Mass Spectrom,2018,32(13):1068-1074.
[6]ZHOU L,LI J,YAN C.Simultaneous determination of three flavonoids and one coumarin by LC-MS/MS:application to a comparative pharmacokinetic study in normal and arthritic rats after oral administration of Daphne genkwa extract[J].Biomed Chromatogr,2018,32(7):e4233.
[7]YUAN Y,WANG Q,YANG M,et al.Application of response surface methodology to vortex-assisted dispersive liquid-liquid extraction for the determination of nicotine and cotinine in urine by GC-MS/MS[J].J Sep Sci,2018,41(10):2261-2268.
[8]JANG K,KIM Y H.Rapid and robust MALDI-TOF MS techniques for microbial identification:a brief overview of their diverse applications[J].J Microbiol,2018,56(4):209-216.
[9]TREVISOI L E,BAIL L,RODRIGUES L S,et al.Matrix-assisted laser desorption ionization-time of flight:a promising alternative method of identifying the major coagulase-negative Staphylococci species[J].Rev Soc Bras Med Trop,2018,51(1):85-87.
[10]GAO L,GU Y,CHEN F,et al.Optimal matrix preparation methods for matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry profiling of low molecular weight peptides in human saliva and serum samples[J].Chin J Dent Res,2018,21(1):51-61.
[11]KLOSE M,THEINER S,KORNAUTH C,et al.Bioimaging of isosteric osmium and ruthenium anticancer agents by LA-ICP-MS[J].Metallomics,2018,10(3):388-396.
[12]YANG Y,LUO L,LI H P,et al.Analysis of metallic nanoparticles and their ionic counterparts in complex matrix by reversed-phase liquid chromatography coupled to ICP-MS[J].Talanta,2018,182:156-163.
[13]ENGHOLM-KELLER K,LARSEN M R.Technologies and challenges in large-scale phosphoproteomics[J].Proteomics,2013,13(6):910-931.
[14]GUO H,ISSERLIN R,LUGOWSKI A,et al.Large-scale label-free phosphoproteomics:from technology to data interpretation[J].Bioanalysis,2014,6(18):2403-2420.
[15]CHOUDHARY C,WEINERT B T,NISHIDA Y,et al.The growing landscape of lysine acetylation links metabolism and cell signalling.Nat Rev Mol[J].Nature Reviews Molecular Cell Biology,2014,15(8):536-550.
[16]GUO A,GU H,ZHOU J,et al.Immunoaffinity enrichment and mass spectrometry analysis of protein methylation[J].Mol Cell Proteomics Mcp,2014,13(1):372-387.
[17]HELBIG A 0,GAUCI S,RAIJMAKERS R,et al.Profiling of Nacetylated protein termini provides in-depth insights into the Nterminal nature of the proteome[J].Mol Cell Proteomics,2010,9(5):928-939.
[18]KIM W,BENNETT E J,HUTTLIN E L,et al.Systematic and quantitative assessment of the ubiquitin modified proteome[J].Mol Cell,2011,44(2):325-340.
[19]PAN S,CHEN R,AEBERSOLD R,et al.Mass spectrometry based glycoproteomics--from a proteomics perspective[J].Mol Cell Proteomics,2011,10(1):R110-R3251.
[20]THOLEY A,BECKER A.Top-down proteomics for the analysis of proteolytic events-Methods,applications and perspectives[J].Biochim Biophys Acta Mol Cell Res,2017,1864(11PtB):2191-2199.
[21]WANG Q,ZHANG M,TOMITA T,et al.Selected reaction monitoring approach for validating peptide biomarkers[J].Proc Natl Acad Sci USA,2017,114(51):13519-13524.
[22]REPETTO 0,De RE V,De PAOLI A,et al.Identification of protein clusters predictive of tumor response in rectal cancer patients receiving neoadjuvant chemo-radiotherapy[J].Oncotarget,2017,8(17):28328-28341.
[23]CHEN I,XUE L,HSU C,et al.Phosphoproteins in extracellular vesicles as candidate markers for breast cancer[J].Proc Natl Acad Sci USA,2017,114(12):3175-3180.
[24]SIMONI Y,MELISSA C,LI S,et al.Mass cytometry:a powerful tool for dissecting the immune landscape[J].Curr Opin Immunol,2016,51:187-196.
[25]Spitzer M H,Nolan G P.Mass cytometry:single cells,many features[J].Cell,2016,165(4):780-791.
[26]BENDALL S C,NOLAN G P,ROEDERER M,et al.A deep profiler's guide to cytometry[J].Trends Immunol,2012,33(7):323-332.
[27]SUBRAHMANYAM P B,DONG Z,GUSENLEITNER D,et al.Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients[J].J Immunother Cancer,2018,6(1):18.
[28]KRIEG C,NOWICKA M,GUGLIETTA S,et al.High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy[J].Nat Med,2018,24(2):144-153.
[29]CHANG C,QIU J,0 SULLIVAN D,et al.Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression[J].Cell,2015,162(6):1229-1241.
[30]HO P,BIHUNIAK J D,MACINTYRE A N,et al.Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell Responses[J].Cell,2015,162(6):1217-1228.
[31]LIBERTI M V,DAI Z,WARDELL S E,et al.A predictive model for selective targeting of the warburg effect through GAPDH inhibition with a natural product[J].Cell Metab,2017,26(4):648-659.
[32]XU Y,ZHENG X,QIU Y,et al.Distinct Metabolomic Profiles of Papillary Thyroid Carcinoma and Benign Thyroid Adenoma[J].J Proteome Res,2015,14(8):3315-3321.
[33]MATHE E A,PATTERSON A D,HAZNADAR M,et al.Noninvasive urinary metabolomic profiling identifies diagnostic and prognostic markers in lung cancer[J].Cancer Res,2014,74(12):3259-3270.
[34]PARRIS B A,SHAW E,PANG B,et al.Somatic mutations and immune checkpoint biomarkers[J].Respirology,2019,24(3):215-226.
[35]SHEPHERD P,SHEATH K L,TIN S T,et al.Lung cancer mutation testing:a clinical retesting study of agreement between a real-time PCR and a mass spectrometry test[J].Oncotarget,2017,8(60):101437.
[2]LENEY A C,HECK A J R.Native mass spectrometry:what is in the name[J]?J Am Soc Mass Spectrom,2017,28(1):5-13.
[3]YANG H,NING L,LIU S.Determination of peptide and protein disulfide linkages by MALDI mass spectrometry[J].Top Curr Chem,2013,331(15):79-116.
[4]LEE M J,KIM H J.Development of an immunoaffinity chromatography and LC-MS/MS method for the determination of 6zearalenones in animal feed[J].PLoS One,2018,13(3):e193584.
[5]CHENG X,LIU K,LIU Y,et al.Development and validation an LCMS/MS method for determination of caspofungin in dried blood spots[J].Rapid Commun Mass Spectrom,2018,32(13):1068-1074.
[6]ZHOU L,LI J,YAN C.Simultaneous determination of three flavonoids and one coumarin by LC-MS/MS:application to a comparative pharmacokinetic study in normal and arthritic rats after oral administration of Daphne genkwa extract[J].Biomed Chromatogr,2018,32(7):e4233.
[7]YUAN Y,WANG Q,YANG M,et al.Application of response surface methodology to vortex-assisted dispersive liquid-liquid extraction for the determination of nicotine and cotinine in urine by GC-MS/MS[J].J Sep Sci,2018,41(10):2261-2268.
[8]JANG K,KIM Y H.Rapid and robust MALDI-TOF MS techniques for microbial identification:a brief overview of their diverse applications[J].J Microbiol,2018,56(4):209-216.
[9]TREVISOI L E,BAIL L,RODRIGUES L S,et al.Matrix-assisted laser desorption ionization-time of flight:a promising alternative method of identifying the major coagulase-negative Staphylococci species[J].Rev Soc Bras Med Trop,2018,51(1):85-87.
[10]GAO L,GU Y,CHEN F,et al.Optimal matrix preparation methods for matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry profiling of low molecular weight peptides in human saliva and serum samples[J].Chin J Dent Res,2018,21(1):51-61.
[11]KLOSE M,THEINER S,KORNAUTH C,et al.Bioimaging of isosteric osmium and ruthenium anticancer agents by LA-ICP-MS[J].Metallomics,2018,10(3):388-396.
[12]YANG Y,LUO L,LI H P,et al.Analysis of metallic nanoparticles and their ionic counterparts in complex matrix by reversed-phase liquid chromatography coupled to ICP-MS[J].Talanta,2018,182:156-163.
[13]ENGHOLM-KELLER K,LARSEN M R.Technologies and challenges in large-scale phosphoproteomics[J].Proteomics,2013,13(6):910-931.
[14]GUO H,ISSERLIN R,LUGOWSKI A,et al.Large-scale label-free phosphoproteomics:from technology to data interpretation[J].Bioanalysis,2014,6(18):2403-2420.
[15]CHOUDHARY C,WEINERT B T,NISHIDA Y,et al.The growing landscape of lysine acetylation links metabolism and cell signalling.Nat Rev Mol[J].Nature Reviews Molecular Cell Biology,2014,15(8):536-550.
[16]GUO A,GU H,ZHOU J,et al.Immunoaffinity enrichment and mass spectrometry analysis of protein methylation[J].Mol Cell Proteomics Mcp,2014,13(1):372-387.
[17]HELBIG A 0,GAUCI S,RAIJMAKERS R,et al.Profiling of Nacetylated protein termini provides in-depth insights into the Nterminal nature of the proteome[J].Mol Cell Proteomics,2010,9(5):928-939.
[18]KIM W,BENNETT E J,HUTTLIN E L,et al.Systematic and quantitative assessment of the ubiquitin modified proteome[J].Mol Cell,2011,44(2):325-340.
[19]PAN S,CHEN R,AEBERSOLD R,et al.Mass spectrometry based glycoproteomics--from a proteomics perspective[J].Mol Cell Proteomics,2011,10(1):R110-R3251.
[20]THOLEY A,BECKER A.Top-down proteomics for the analysis of proteolytic events-Methods,applications and perspectives[J].Biochim Biophys Acta Mol Cell Res,2017,1864(11PtB):2191-2199.
[21]WANG Q,ZHANG M,TOMITA T,et al.Selected reaction monitoring approach for validating peptide biomarkers[J].Proc Natl Acad Sci USA,2017,114(51):13519-13524.
[22]REPETTO 0,De RE V,De PAOLI A,et al.Identification of protein clusters predictive of tumor response in rectal cancer patients receiving neoadjuvant chemo-radiotherapy[J].Oncotarget,2017,8(17):28328-28341.
[23]CHEN I,XUE L,HSU C,et al.Phosphoproteins in extracellular vesicles as candidate markers for breast cancer[J].Proc Natl Acad Sci USA,2017,114(12):3175-3180.
[24]SIMONI Y,MELISSA C,LI S,et al.Mass cytometry:a powerful tool for dissecting the immune landscape[J].Curr Opin Immunol,2016,51:187-196.
[25]Spitzer M H,Nolan G P.Mass cytometry:single cells,many features[J].Cell,2016,165(4):780-791.
[26]BENDALL S C,NOLAN G P,ROEDERER M,et al.A deep profiler's guide to cytometry[J].Trends Immunol,2012,33(7):323-332.
[27]SUBRAHMANYAM P B,DONG Z,GUSENLEITNER D,et al.Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients[J].J Immunother Cancer,2018,6(1):18.
[28]KRIEG C,NOWICKA M,GUGLIETTA S,et al.High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy[J].Nat Med,2018,24(2):144-153.
[29]CHANG C,QIU J,0 SULLIVAN D,et al.Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression[J].Cell,2015,162(6):1229-1241.
[30]HO P,BIHUNIAK J D,MACINTYRE A N,et al.Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell Responses[J].Cell,2015,162(6):1217-1228.
[31]LIBERTI M V,DAI Z,WARDELL S E,et al.A predictive model for selective targeting of the warburg effect through GAPDH inhibition with a natural product[J].Cell Metab,2017,26(4):648-659.
[32]XU Y,ZHENG X,QIU Y,et al.Distinct Metabolomic Profiles of Papillary Thyroid Carcinoma and Benign Thyroid Adenoma[J].J Proteome Res,2015,14(8):3315-3321.
[33]MATHE E A,PATTERSON A D,HAZNADAR M,et al.Noninvasive urinary metabolomic profiling identifies diagnostic and prognostic markers in lung cancer[J].Cancer Res,2014,74(12):3259-3270.
[34]PARRIS B A,SHAW E,PANG B,et al.Somatic mutations and immune checkpoint biomarkers[J].Respirology,2019,24(3):215-226.
[35]SHEPHERD P,SHEATH K L,TIN S T,et al.Lung cancer mutation testing:a clinical retesting study of agreement between a real-time PCR and a mass spectrometry test[J].Oncotarget,2017,8(60):101437.